Geode Capital Management LLC boosted its holdings in Clearside Biomedical Inc (NASDAQ:CLSD) by 4.9% during the fourth quarter, Holdings Channel reports. The fund owned 303,512 shares of the company’s stock after buying an additional 14,181 shares during the period. Geode Capital Management LLC’s holdings in Clearside Biomedical were worth $324,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Alambic Investment Management L.P. acquired a new position in Clearside Biomedical in the fourth quarter valued at approximately $26,000. SG Americas Securities LLC acquired a new position in Clearside Biomedical in the fourth quarter valued at approximately $37,000. Renaissance Technologies LLC acquired a new position in Clearside Biomedical in the third quarter valued at approximately $216,000. Rhumbline Advisers lifted its holdings in Clearside Biomedical by 48.5% in the fourth quarter. Rhumbline Advisers now owns 36,979 shares of the company’s stock valued at $40,000 after acquiring an additional 12,076 shares during the last quarter. Finally, Virtu Financial LLC acquired a new position in Clearside Biomedical in the fourth quarter valued at approximately $57,000. Hedge funds and other institutional investors own 32.63% of the company’s stock.
NASDAQ:CLSD opened at $1.28 on Wednesday. The company has a debt-to-equity ratio of 0.40, a quick ratio of 4.10 and a current ratio of 4.10. Clearside Biomedical Inc has a 52 week low of $0.99 and a 52 week high of $15.33. The firm has a market cap of $43.24 million, a price-to-earnings ratio of -0.48 and a beta of -1.21.
A number of research firms have commented on CLSD. Zacks Investment Research cut Clearside Biomedical from a “hold” rating to a “sell” rating in a research note on Friday, March 15th. ValuEngine cut Clearside Biomedical from a “hold” rating to a “sell” rating in a research note on Wednesday, May 1st. Finally, Cowen restated a “hold” rating on shares of Clearside Biomedical in a research note on Tuesday, January 22nd. Four equities research analysts have rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $10.32.
WARNING: “Clearside Biomedical Inc (CLSD) Position Lifted by Geode Capital Management LLC” was posted by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The legal version of this piece can be viewed at https://www.baseballdailydigest.com/news/2019/05/15/clearside-biomedical-inc-clsd-position-lifted-by-geode-capital-management-llc.html.
Clearside Biomedical Profile
Clearside Biomedical, Inc, a late-stage clinical biopharmaceutical company, develops pharmacological therapies to restore and preserve vision for people with serious eye diseases. It develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion.
Want to see what other hedge funds are holding CLSD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Clearside Biomedical Inc (NASDAQ:CLSD).
Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.